Related Experiment Video
Updated: Jun 18, 2025

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Advances in Care and Outcomes for Children with Cystic Fibrosis
Bob Z Sun1, Gregory S Sawicki1
1Division of Pulmonary Medicine, Department of Pediatrics, Boston Children's Hospital, 300 Longwood Avenue, BCH 3121, Boston, MA 02115, USA; Harvard Medical School, Harvard University, 25 Shattuck Street, Boston, MA 02115, USA.
Insights
Cystic Fibrosis (CF) care is improving for children with new therapies and early diagnosis. However, challenges remain in optimizing outcomes for all CF patients.
Area of Science:
- Pediatric Pulmonology
- Genetic Disorders
- Medical Therapeutics
Background:
- Cystic Fibrosis (CF) is a genetic disorder affecting multiple systems, notably the lungs and pancreas.
- Key manifestations include mucus buildup, lung infections, and digestive issues.
- Current CF care focuses on early diagnosis and management of symptoms.
Purpose of the Study:
- To review the evolving landscape of pediatric cystic fibrosis care.
- To highlight advancements in diagnosis and treatment.
- To identify persistent challenges in optimizing CF patient outcomes.
Main Methods:
- Review of current literature on pediatric cystic fibrosis care.
- Analysis of the impact of newborn screening and early interventions.
- Evaluation of novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Main Results:
- Early diagnosis and nutritional support improve outcomes.
- Chronic therapies enhance mucociliary clearance and reduce infections.
- CFTR modulator therapies are revolutionizing pediatric CF care.
Conclusions:
- Pediatric CF care has significantly advanced, improving patient outcomes.
- Widespread availability of novel therapies offers transformative potential.
- Optimizing care and outcomes for all children with CF remains a critical challenge.
Abstract:
The landscape of care for children with cystic fibrosis (CF), a genetic disorder of chloride transport with multisystem manifestations including inspissated mucus, recurrent sinopulmonary infections, obstructive lung disease, and exocrine pancreatic insufficiency, is rapidly changing. Early diagnosis via newborn screening enabling timely nutritional support, chronic therapies to improve mucociliary clearance, and prompt treatment of pulmonary infections have improved overall outcomes in children with CF. More widespread availability of novel cystic fibrosis transmembrane conductance regulator modulator therapies for children continues to revolutionize pediatric CF care.However, significant challenges exist to optimize care and outcomes for all children with CF.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

